MCGAULEY THOMAS 4

What Happened

• Thomas McGauley, interim Chief Financial Officer of Tenax Therapeutics (TENX), exercised derivative rights to acquire 50,000 shares on January 30, 2026. The exercise price reported was $0.00, so the reported cash consideration for this transaction was $0. The Form 4 was filed on February 3, 2026.

Key Details

• Transaction date: 2026-01-30 (reported on Form 4 filed 2026-02-03)
• Transaction type/code: Exercise of derivative (code M)
• Shares acquired: 50,000; exercise price: $0.00; reported cash paid: $0
• Shares owned after transaction: Not specified in the provided filing excerpt
• Footnote: Options vest 50% on Jan 30, 2026 and 50% on May 31, 2026, subject to continuous service (footnote F1)
• Timeliness: Filing date (Feb 3) is within the typical two-business-day Form 4 deadline for a Jan 30 transaction

Context

• This was an exercise of vested derivative awards (options or similar), not a sale. The filing does not report any immediate sale or disposition of the shares, so the transaction appears to be an acquisition/vesting event rather than a cashless exercise-and-sell. A $0.00 exercise price implies no cash outlay was required at exercise according to the report; it may reflect previously granted awards with no strike. As always, this is a factual report of insider activity and should not be taken as a statement of company value or a recommendation to buy or sell.